AG
IOVA icon

Aperio Group’s Iovance Biotherapeutics IOVA Stock Holding History

Aperio Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$876K Buy
18,885
+1,316
+7% +$52.2K ﹤0.01% 1669
2020
Q3 		$578K Buy
17,569
+2,567
+17% +$78.7K ﹤0.01% 1742
2020
Q2 		$412K Sell
15,002
-1,490
-9% -$49K ﹤0.01% 1866
2020
Q1 		$494K Buy
16,492
+13,876
+530% +$368K ﹤0.01% 1654
2019
Q4 		$72K Buy
+2,616
New +$59.5K ﹤0.01% 2287
2019
Q3 		– Sell
-3,510
Closed -$86K – 2528
2019
Q2 		$86K Buy
+3,510
New +$52.9K ﹤0.01% 2427

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aperio Group's IOVA Position: Q4 2020 in Review

Aperio Group increased its Iovance Biotherapeutics (IOVA) stake by 7.5% in Q4 2020, buying an estimated $52.2K and bringing the position to 18,885 shares worth $876K. The position accounts for ﹤0.01% of the portfolio, ranked #1669.

Aperio Group first reported a position in IOVA in Q2 2019 and has held it in 6 quarters since. 269 funds tracked by Wall St. Rank hold IOVA as of Q4 2020.

  • Aperio Group held 18,885 shares of Iovance Biotherapeutics worth $876K as of Q4 2020.
  • Aperio Group bought 1,316 Iovance Biotherapeutics shares in Q4 2020, an estimated $52.2K.
  • Iovance Biotherapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1669 holding.
  • Aperio Group first reported a position in Iovance Biotherapeutics in Q2 2019 and has held it in 6 quarters since.
  • 269 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.